Search tips
Search criteria 


Logo of jrcrLink to Publisher's site
J Radiol Case Rep. 2017 April; 11(4): 30–37.
Published online 2017 April 30. doi:  10.3941/jrcr.v11i4.3092
PMCID: PMC5439453

Radiologic Findings in Gabapentin-Induced Myositis


Throughout recent years, Gabapentin has become increasingly used for the treatment of neuropathic pain. We report on a case of a 31 year old female who presented to the emergency department with unilateral leg pain, weakness, and swelling after increasingly titrating her Gabapentin dosage over three weeks. Magnetic resonance imaging confirmed the presence of myositis confined to the left thigh and the patient’s symptoms and laboratory abnormalities resolved following Gabapentin cessation. While Gabapentin-induced myositis and rhabdomyolysis is a rare entity, it should be a diagnostic consideration for radiologists, particularly in the absence of infection or trauma.

Keywords: Gabapentin, Drug-Induced, Myositis, Myopathy, Rhabdomyolysis, Computed Tomography, CT, Magnetic Resonance Imaging, MRI, Musculoskeletal, MSK, Case Report


A 31 year old female presented to the emergency department (ED) with left thigh pain and increasing leg circumference, which began one day prior to presentation. She had woken up with generalized stiffness and with both legs and arms in flexion requiring assistance for full extension. The patient also reported left leg weakness, pain and loss of sensation. There was no history of prolonged lower extremity immobilization prior to admission, nor was there a history of trauma or injury otherwise to the left leg. No clinical evidence was present to suggest underlying infection or cellulitis. The patient denied any fever, diaphoresis, nausea, vomiting, memory loss, or drug intoxication. Her past medical history included bipolar disorder, prior substance abuse, remote trauma (motor vehicle accident), and sciatica secondary to nerve impingement. There was no history of diabetes or renal impairment. Her medications on admission were: Hydromorphone, Naproxen, Gabapentin, Trazodone, Paroxetine, and Bupropion. She had been compliant with her medications with no alterations in dosages, except for her Gabapentin, which had been titrated from 1200 mg to 3000 mg once daily over the 3 weeks preceding her presentation. No allergies or history of an adverse drug reaction were reported. Upon admission to the ED, the patient’s Gabapentin was discontinued and her Hydromorphone and Naproxen were continued for pain control along with all psychotropic medications (Trazadone, Paroxetine, Bupropion). After initial assessment in the ED, multiple clinical services were consulted.

On examination by the Neurology service, there was found to be diffuse pain from the left buttock to the left knee along with mild associated muscle weakness (4/5) on knee flexion. The patient also experienced pain with internal and external rotation of the left hip. Tone and muscle bulk were normal bilaterally and peripheral pulses were present and unremarkable. The patient exhibited impaired sensation to touch on the lateral aspect of the left leg.

Orthopedic and Vascular Surgery consultations reported full range of motion, supple muscles in the left buttock, thigh and calf with no evidence of vascular compromise. The decision to not obtain compartmental pressures was made given that the clinical findings were not in keeping with a diagnosis of compartment syndrome.

The patient’s bloodwork showed an elevated creatine kinase of 44360 U/L (reference range: 38–176 U/L). Her renal function tests were normal and urine toxicology immunoassay was negative. The patient’s white cell count was 3.4 ×109 (reference range: 4.0–11×109), hemoglobin 138 g/L (reference range: 120–155 g/L), platelets 126×109 (reference range: 150–400×109), and her electrolyte panel was within normal limits. CRP was elevated at 8 mg/L (reference range: <3.1 mg/L) as was her lactate dehydrogenase at 1172 U/L (reference range: 90–240 U/L).

Given the unilateral nature of this presentation, the initial diagnostic imaging test ordered was an ultrasound of the left lower extremity. Doppler ultrasound demonstrated normal laminar flow through the venous and arterial structures with diffuse areas of hypoechogenicity in the subcutaneous tissues of the left medial thigh, compatible with edema (Fig. 1). With a negative Doppler ultrasound, the next diagnostic imaging test ordered was a CT angiogram (CTA). There was no evidence of vascular compromise or nerve compression on CTA, however, a hypoattenuating lesion was seen in the adductor compartment of the left medial thigh (Fig. 2).

Figure 1
31 year old female with Gabapentin-induced myositis.
Figure 2
31 year old female with Gabapentin-induced myositis.

MRI with administration of intravenous contrast using 7 cc of Gadovist (Gadobutrol) was subsequently performed for further characterization. Profound subcutaneous and muscular edema was noted throughout the left thigh on T2 fat suppressed (FS) inversion recovery images (Fig. 3 and Fig. 4). The patient’s legs measured 22.9 cm and 17.4 cm on the left and right, respectively (Fig. 3). The increased T2 signal involved the adductor magnus, tensor fascia lata, vastus lateralis, gluteus medius, and gluteus maximus and was felt to be most compatible with inflammatory changes (Fig. 3, Fig. 4). Moreover, there was tracking of this fluid along the muscle compartments, which was best demonstrated on axial images (Fig. 5). On post-contrast T1 FS sequences, heterogeneous enhancement was seen involving the gluteus maximus, adductor magnus, tensor fascia lata, and gracilis muscle (Fig. 6 and Fig. 7).

Figure 3
31 year old female with Gabapentin-induced myositis.
Figure 4
31 year old female with Gabapentin-induced myositis.
Figure 5
31 year old female with Gabapentin-induced myositis.
Figure 6
31 year old female with Gabapentin-induced myositis.
Figure 7
31 year old female with Gabapentin-induced myositis.

This patient was closely observed by the medical team and received aggressive IV fluid resuscitation. After cessation of Gabapentin and IV hydration, the patient’s creatine kinase levels dropped to 4000 U/L (reference range: 38–176 U/L) within 24 hours. The patient was discharged with a recommendation for Gabapentin to be avoided in the future. Short-term clinical follow up and outpatient laboratory studies showed a normal creatine kinase level and symptom resolution.


Etiology & Demographics

Drugs that are well known to cause rhabdomyolysis include: Atorvastatin, Simvastatin, Interferon alpha-2b, antimicrotubule chemotherapy agents (ie: Gemcitabine), protease inhibitors (ie: Saquinavir), and mitochondrial toxins [15]. The three primary mechanisms in which rhabdomyolysis induction occurs are: impaired autophagy, metabolic impairment, or medication induced autoimmune reactions [2].

Gabapentin is a second generation antiepileptic drug that been increasingly used for the treatment of neuropathic pain. In fact, it has become a first line treatment for neuropathic pain as per many societal guidelines, including the Canadian Pain Society [6]. In the setting of neuropathic pain, Gabapentin dampens neuronal excitability via calcium channel modulation to provide pain relief [7]. Common side effects of Gabapentin include ataxia, drowsiness, fatigue, and dizziness [7,8]. Myositis and rhabdomyolysis, however, are a very rare side effect of Gabapentin use, and to our knowledge, there have been only six reported cases in the current literature [913]. Given that Gabapentin has also been found to modulate calcium channels in skeletal myocytes [14], it has been hypothesized that this may be the pathway in which Gabapentin-induced myositis and rhabdomyolysis develops, but the exact etiology and pathogenesis is not well understood at this time [7]. Given the rarity of this diagnostic entity, the demographics also remain poorly delineated. It does not, however, appear that drug-induced myositis and rhabdomyolysis has a specific age or gender predilection.

Clinical & Imaging findings

Rhabdomyolysis reflects the breakdown of muscle, which subsequently releases myoglobin, phosphate, potassium, urate, and creatine kinase. Rhabdomyolysis is most often a clinical diagnosis, with its main features being muscle pain, weakness, tenderness, swelling, and red-brown tinged urine in the setting of grossly elevated serum creatine kinase levels and/or impaired renal function [15].

Drug-induced myositis and rhabdomyolysis, particularly when unilateral, is considered a diagnosis of exclusion, whereby more common entities such as trauma, infection, and vascular occlusion must be ruled out. As demonstrated in this case report, Doppler ultrasound and CTA are often used as the initial diagnostic imaging modalities to rule out vascular thrombosis, hemorrhage, or an overt infectious etiology. In more diagnostically challenging cases, MRI can be of utility to definitively diagnose myopathy or myositis. As seen in this case, MRI’s superior soft tissue characterization allowed for diagnosis of an inflammatory process (myositis) and delineated the extent of pathologic involvement (Fig. 8).

Figure 8
31 year old female with Gabapentin-induced myositis.

MRI revealed diffuse multi-compartmental hyperintense T2 signal (muscle edema) and heterogeneous contrast enhancement within the left medial thigh. Given the absence of trauma and a negative ultrasound and CTA, these MRI findings were strongly favoured to be secondary to an inflammatory process. Moreover, the recent increase of the patient’s Gabapentin dose prior to admission was considered a possible inciting factor. After fluid resuscitation and cessation of Gabapentin, there was rapid improvement and resolution of the rhabdomyolysis and clinical symptoms, thus confirming the imaging diagnosis of Gabapentin-induced myositis and rhabdomyolysis.

It is unclear as to why this patient presented with unilateral symptoms and this unusual clinical presentation therefore required the use of multiple imaging modalities to reach a diagnosis, including MRI. Nevertheless, myositis is a rare, but recognized, adverse effect of Gabapentin use and this case report illustrates the radiologic findings which support a final diagnosis of Gabapentin-induced myositis.

Treatment & Prognosis

The definitive treatment for Gabapentin-induced myositis is drug cessation and treatment of concomitant rhabdomyolysis with aggressive intravenous fluid resuscitation. Moreover, many patients will undergo other supportive therapies, such as correction of electrolyte imbalances. Serial physical exams are required to monitor for end-organ damage (ie: renal failure) or compartment syndrome along with serial laboratory studies to monitor serum electrolytes and ensure resolution of elevated creatine kinase levels. The prognosis of myositis and rhabdomyolysis greatly depends on the underlying etiology as well as the patient’s comorbidities. Nevertheless, if a diagnosis is made promptly with early initiation of treatment, the prognosis remains very favorable. Moreover, the vast majority of patients have been shown to recover full baseline renal function if initially presenting with an acute kidney injury.

Differential Diagnosis

This healthy 31 year old female presented with unilateral leg pain, weakness, and swelling, which would include a differential diagnosis that is greatly dependent upon clinical exam findings and laboratory results. Given that myositis would be considered a diagnosis of exclusion, the most critical differential diagnoses to initially rule out would include:

Muscle Ischemia

Prolonged oxygen deprivation will incite muscle ischemia and rhabdomyolysis. This would include entities such as compartment syndrome and vascular (arterial or venous) thrombosis or embolus. Compartment syndrome can be ruled out clinically, but vascular etiologies are generally assessed through the utilization of Doppler ultrasound or CTA, as seen in this case report.


Numerous bacterial, viral and fungal organisms can lead to muscular infection and rhabdomyolysis. Again, this would often be evident clinically, with the patient presenting with fever, leukocytosis or a history of immunodeficiency. In the setting of an erythematous and warm extremity, ultrasound may be of utility to look for intramuscular or subcutaneous abscess formation.


In nearly all cases, a history of trauma would be provided or evident on clinical examination. Important mechanisms of trauma that lead to rhabdomyolysis include: direct blow trauma, crush injury, electrocution, or high degree skin burns.


Myositis is a rare, but recognized, adverse effect of Gabapentin use. In the correct clinical setting, MRI should be recommended and drug-induced etiologies of myositis should be a diagnostic consideration for radiologists, particularly in the absence of infection or trauma.

Table 1
Differential diagnosis table for skeletal muscle edema and rhabdomyolysis.
Table 2
Summary table for Gabapentin-induced myositis.


computed tomography
computed tomography angiogram
emergency department
fat suppressed
magnetic resonance imaging


1. Klopstock T. Drug-induced myopathies. Curr Opin Neurol. 2008;21(5):590–595. [PubMed]
2. Jones JD, Kirsch HL, Wortmann RL, Pillinger MH. The causes of drug-induced muscle toxicity. Curr Opin Rheumatol. 2014;26(6):697–703. [PubMed]
3. Delavan JA, Chino JP, Vinson EN. Gemcitabine-induced radiation recall myositis. Skeletal Radiol. 2015;44(3):451–455. [PubMed]
4. Rajak S, Sullivan T, Selva D. Orbital myositis: a side effect of interferon alpha 2b treatment. Ophthal Plast Reconstr Surg. 2015;31(1):75. [PubMed]
5. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23(4):317–324. [PubMed]
6. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD. Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–335. [PMC free article] [PubMed]
7. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013;36(3):237–251. [PubMed]
8. Honarmand A, Safavi M, Zare M. Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy. J Res Med Sci. 2011;16(8):1062–1069. [PMC free article] [PubMed]
9. Bilgir O, Calan M, Bilgir F, Kebapçilar L, Yüksel A, Yildiz Y, Sari I. Gabapentin-induced rhabdomyolysis in a patient with diabetic neuropathy. Intern Med. 2009;48(12):1085–1087. [PubMed]
10. Lipson J, Lavoie S, Zimmerman D. Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. Am J Kidney Dis. 2005;45(6):e100–e104. [PubMed]
11. Tuccori M, Lombardo G, Lapi F, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. Ann Pharmacother. 2007;41(7):1301–1305. [PubMed]
12. Falconi D, Tattoli F, Brunetti C, De Prisco O, Gherzi M, Marazzi F, Marengo M, Serra I, Tamagnone M, Formica M. Rhabdomyolysis from gabapentin: a case report. G Ital Nefrol. 2015;32(2) [PubMed]
13. Choi MS, Jeon H, Kim HS, Jang BH, Lee YH, Park HS, Kim H, Jin DC. A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy. Hemodial Int. 2017;21(1):E4–E8. [PubMed]
14. Alden KJ, García J. Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther. 2001;297(2):727–735. [PubMed]
15. Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve. 2002;25(3):332–347. [PubMed]

Articles from Journal of Radiology Case Reports are provided here courtesy of EduRad